Neurobo Pharmaceuticals Inc Special Meeting Transcript
Good morning, ladies and gentlemen. Welcome to the special meeting of stockholders of NeuroBo Pharmaceuticals, Inc. I am Andrew Koven, the Chairman of the Board of Directors of NeuroBo Pharmaceuticals, Inc. Thank you all for joining today.
At this time, I call the meeting to order. And there are four items of business on today's agenda.
One, to approve in accordance with applicable NASDAQ rules, the issuance of shares of NeuroBo's common stock, it's consideration under the license agreement dated September 14, 2022, entered into by and between Dong-A ST Co. Limited, or Dong-A and NeuroBo, and pursuant to the securities purchase agreement dated September 14, 2022, entered into by and between Dong-A and NeuroBo, including upon the conversion of shares of NeuroBo's Series A convertible preferred stock issued to Dong-A pursuant to the terms and conditions of the license agreement and the securities purchase agreement.
The exercise of warrants issued to Dong-A pursuant to the terms and conditions of the securities
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)